Though pharmaceutical companies point to research and development costs to justify how they price drugs, a product’s value has no connection to R&D funds, healthcare analyst Joshua Cohen writes in an article published on Forbes.
“Certainly, ongoing and future drug development requires large investments,” Cohen writes. “But again, when price and value are aligned the price is largely disconnected to prior investment.”
To read the article on Forbes, click here.
